X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs DR. REDDYS LAB - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA DR. REDDYS LAB DISHMAN PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 25.1 29.2 86.0% View Chart
P/BV x 3.3 2.9 117.0% View Chart
Dividend Yield % 0.7 0.9 70.3%  

Financials

 DISHMAN PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
DR. REDDYS LAB
Mar-17
DISHMAN PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs3743,397 11.0%   
Low Rs1292,560 5.0%   
Sales per share (Unadj.) Rs197.8856.5 23.1%  
Earnings per share (Unadj.) Rs21.278.0 27.2%  
Cash flow per share (Unadj.) Rs34.7139.9 24.8%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.80.7 118.4%  
Book value per share (Unadj.) Rs179.9739.8 24.3%  
Shares outstanding (eoy) m80.69165.74 48.7%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x1.33.5 36.6%   
Avg P/E ratio x11.938.2 31.1%  
P/CF ratio (eoy) x7.221.3 34.0%  
Price / Book Value ratio x1.44.0 34.7%  
Dividend payout %9.425.7 36.8%   
Avg Mkt Cap Rs m20,306493,632 4.1%   
No. of employees `0000.822.7 3.7%   
Total wages/salary Rs m5,35531,068 17.2%   
Avg. sales/employee Rs Th19,252.76,259.0 307.6%   
Avg. wages/employee Rs Th6,459.51,369.8 471.6%   
Avg. net profit/employee Rs Th2,064.1569.7 362.3%   
INCOME DATA
Net Sales Rs m15,961141,961 11.2%  
Other income Rs m2651,715 15.5%   
Total revenues Rs m16,226143,676 11.3%   
Gross profit Rs m4,10324,722 16.6%  
Depreciation Rs m1,09110,266 10.6%   
Interest Rs m944634 149.0%   
Profit before tax Rs m2,33415,537 15.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m1349 0.3%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6242,965 21.0%   
Profit after tax Rs m1,71112,921 13.2%  
Gross profit margin %25.717.4 147.6%  
Effective tax rate %26.719.1 140.0%   
Net profit margin %10.79.1 117.8%  
BALANCE SHEET DATA
Current assets Rs m11,01896,837 11.4%   
Current liabilities Rs m9,51784,199 11.3%   
Net working cap to sales %9.48.9 105.6%  
Current ratio x1.21.2 100.7%  
Inventory Days Days11073 150.6%  
Debtors Days Days3598 35.7%  
Net fixed assets Rs m16,304102,552 15.9%   
Share capital Rs m161829 19.5%   
"Free" reserves Rs m12,907121,792 10.6%   
Net worth Rs m14,516122,621 11.8%   
Long term debt Rs m4,1895,449 76.9%   
Total assets Rs m29,805218,165 13.7%  
Interest coverage x3.525.5 13.6%   
Debt to equity ratio x0.30 649.5%  
Sales to assets ratio x0.50.7 82.3%   
Return on assets %8.96.2 143.4%  
Return on equity %11.810.5 111.9%  
Return on capital %17.512.9 135.9%  
Exports to sales %24.854.6 45.4%   
Imports to sales %3.79.4 40.0%   
Exports (fob) Rs m3,95677,520 5.1%   
Imports (cif) Rs m59613,274 4.5%   
Fx inflow Rs m4,95281,670 6.1%   
Fx outflow Rs m69726,355 2.6%   
Net fx Rs m4,25555,315 7.7%   
CASH FLOW
From Operations Rs m2,78621,444 13.0%  
From Investments Rs m-1,529-18,404 8.3%  
From Financial Activity Rs m-941-3,692 25.5%  
Net Cashflow Rs m316-1,144 -27.7%  

Share Holding

Indian Promoters % 61.4 25.5 240.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 5.4 68.5%  
FIIs % 12.7 35.3 36.0%  
ADR/GDR % 0.0 18.5 -  
Free float % 22.1 15.3 144.4%  
Shareholders   46,261 75,885 61.0%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  PFIZER  ALKEM LABORATORIES  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Red; PSU & Energy Stocks Decline(01:30 pm)

Indian share markets continued to trade in red during the noon session weak Asian markets. PSU stocks and energy stocks are witnessing majority of the selling activity.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS